Table 2.
Demographics, clinical, and imaging characteristics of the subset of PD sample with CSF measurements
| Subject groups | PD, No CSF | PD, CSF | p value |
|---|---|---|---|
| n | 68 | 35 | |
| PD-NC:PD-MCI | 37:31 | 27:8 | |
| Age (y) | 65.4 ± 10 | 64.4 ± 9.6 | 0.6c |
| Age range | 41.8–85.5 | 47.8–87.3 | |
| Gender (male, %) | 49, 72.1% | 20, 57.1% | 0.1a |
| Disease duration (mo) | 25.7 ± 0.6 | 21.9 ± 0.5 | <0.001b |
| UPDRS | 27.3 ± 11.1 | 25.7 ± 10.8 | 0.6c |
| MMSE | 28.6 ± 1.3 | 28.97 ± 1.0 | 0.2b |
| PBVC (%) | −0.73 ± 0.8 | −0.58 ± 0.6 | 0.5b |
| Ventricular enlargement (%) | 4.3 ± 6.6 | 3.90 ± 4.8 | 0.8b |
| CSF T-Tau (pg/mL) | 130.1 ± 102.8 | ||
| CSF P-Tau (pg/mL) | 48.1 ± 20.7 | ||
| CSF AB42 (pg/mL) | 966.2 ± 300.0 | ||
| CSF AB40 (pg/mL) | 10,968.3 ± 4610.0 | ||
| CSF AB42/AB40 ratio | 0.10 ± 0.03 | ||
| CSF A-SYN (pg/mL) |
92.4 ± 49.0 |
||
| PD, No CSF |
PD, CSF |
p value |
|
| n | 65 | 35 | |
| PD-NC:PD-MCI | 37:28 | 27:8 | |
| Age (y) | 65.2 ± 10.1 | 64.4 ± 9.6 | 0.7c |
| Age range | 41.8–85.5 | 47.8–87.3 | |
| Gender (male, %) | 46, 71% | 20, 57.1% | 0.2a |
| Disease duration (mo) | 25.8 ± 5.2 | 21.9 ± 3.1 | <0.001b |
| UPDRS | 27.1 ± 11.1 | 25.7 ± 10.8 | 0.5c |
| MMSE | 28.6 ± 1.3 | 29.0 ± 1.0 | 0.2b |
| PBVC (%) | −0.72 ± 0.8 | −0.58 ± 0.6 | 0.6b |
| VIENA (%) | 4.2 ± 5.6 | 3.1 ± 4.3 | 0.3t |
| CSF T-Tau (pg/mL) | 130.1 ± 102.8 | ||
| CSF P-Tau (pg/mL) | 48.1 ± 20.7 | ||
| CSF Aβ42 (pg/mL) | 966.2 ± 300.0 | ||
| CSF Aβ40 (pg/mL) | 10,968.3 ± 4610.0 | ||
| CSF Aβ42/Aβ40 ratio | 0.10 ± 0.03 | ||
| CSF α-synuclein (pg/mL) | 92.4 ± 49.0 |
Values expressed as mean ± SD.
Key: CSF, cerebrospinal fluid; MMSE, Mini–Mental State Exam, PBVC, percentage brain volume change; UPDRS, Unified Parkinson's Disease Rating Scale III; VIENA, ventricular enlargement.
a
χD test.
b
Wilcoxon rank-sum test.
c
Student t test.